Merck sells API business, drug portfolio in $1B deal

06/28/2013 | Bloomberg · Pharmaceutical Business Review Online

Aspen Group agreed to buy Merck & Co.'s active pharmaceutical ingredient manufacturing business and purchase an option to buy a portfolio of 11 finished dose form molecules that target a range of conditions. The deal is valued at $1 billion. Aspen said the acquisition, which is expected to be finalized this year, will bolster its growth in Latin America, the Asia-Pacific region and other emerging markets.

View Full Article in:

Bloomberg · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ